ďISĒ the IDENTICAL Silver
that Bill McFarland used
The ďHistoryĒ of Bill McFarland
Bill McFarland, a Louisiana-based businessman was introduced to MSP by a physician friend [Dr. Cordot]. He began to use it personally for minor viral infections and recommended it to friends for oral and topical use for a variety of clinical conditions. As he became convinced of its efficacy for both viral and bacterial infections, he speculated that it might have positive effects in ameliorating serious, difficult-to-treat infectious diseases-and that it might be even more effective when administered intravenously. He convinced a physician in Mexico to administer the infusions and developed a preliminary experimental protocol in conjunction with the Mexican physician, and Joe J. Cardot, N.D., a Colorado [M.D. and] naturopathic physician, using an updated potentiated MSP product.
Materials and Methods In 1997:
McFarland recruited three subjects with HIV to participate in clinical trials with potentiated MSP. The initial protocol involved progressively increasing amounts and concentrations of MSP administered orally for 30-60 days, followed by a series of intravenous infusions of MSP in concentrations ranging from 40PPM to 1,500 PPM. Medical records for the three subjects were obtained - too as great a degree as possible Ė from the subjectsí personal physicians, and from the NO AIDS Task Force at Charity Hospital in New Orleans, LA. MSP was initially provided by Discovery Experimental of Tampa, Florida, which at that time manufactured McFarlandís silver, and later by his own company, Natrition, Inc. [ http://natrition.com/ ]
Subjects were started on oral MSP 400 PPM at standard dosages (several teaspoons daily in divided doses) for approximately one month prior to administering MSP intravenously. Oral MSP was continued throughout the test period. One hundred twenty ml. MSP in concentrations of 40, 400 and 1,500 PPM (2 SUBJECTS [AP and RC], one time each), in a carrier solution of 500 cc � normal saline Ėto which 10 cc DMSO was added (it was believed that DMSO would enhance the efficacy of MSP) Ė were infused over two-three hours. Physicians in Mexico and the US monitored the patients for twenty-four hours a day for 5-7 days after each IV infusion, and once a week thereafter, via office visits and almost daily telephone conversations.
Results: The medical history and limited laboratory results of the three subjects in this study are outlined below:
AP is a white male, born in 1967. Records from Charity Hospital reveal that he was diagnosed with HIV in February 1993. At that time, he weighed 137 pounds, and his only abnormal physical finding was swollen inguinal lymph nodes. In April 1995, AP was treated for nausea, vomiting, diarrhea, and shingles. In August 1996, he began to complain of anxiety, diarrhea, and weight loss, for which he began to seek more regular medical treatment. Although intermittent courses of antibiotics were prescribed for diarrhea, Zorvirax for shingles, and AZT for HIV, AP seldom completed a course of any of these medications. At the time he entered the experimental trial with potentiated MSP in October of 1997, AP was on no other medication. He weighed 132lbs. And was unable to walk without assistance due to fatigue and weakness. His viral load was over 750,000 Ė the maximum detectable limit of the instrument. APís first IV infusion was in December of 1997. Therapies administered in this program are outlined in Table I. Thirty days and five MSP infusions later; APís viral load was 39,000. One month later, with no additional infusions, the viral load was down to 400 (Table I) (Fig. 1).
RC is a Puerto Rican male, born in 1950. He does not smoke cigarettes, drinks alcohol moderately, and eats a healthy diet. He does smoke marijuana. RCís male roommate died of AIDS/HIV at Charity Hospital in 1986 at the age of 30. RCís medical history includes Hepatitis A and B. RC has been a waiter most of his adult life and also worked as a carpenter with his father on weekends, renovating houses. In 1987, RC enrolled in Charity Hospitalís "No Aids Task Force" where he tested positive for HIV. No viral load or T cell count data are available. RC believed he had only two years to live. For the next ten years, he kept waiting to die Ė but did not. In the summer of 1997, he began to note a decrease in energy, and increased requirement for sleep, causing him to discontinue his work as a carpenter. He volunteered for the experimental MSP treatment program in November 1997. RC received five IV infusions on the same date and dosage as AP (Table I). He received an additional 400-PPM infusion on 27 February. He continued on oral MSP 400 until June of 1998, when he discontinued participation in the program. RC noted a dramatic restoration of his energy levels, and returned to his former occupation as a waiter, and usually worked up to two shifts a day from 12:00 noon until 12:00 or 1:00 in the morning. Because of his restored energy levels, RC no longer felt a need to visit McFarlandís office. Although RC would not return to the office, McFarland went to his place of employment with a physician friend every weekend in March and April. RC promised to obtain additional records form the State of Louisiana, but he unfortunately never followed through.
RM is a white female, born in 1976, who was diagnosed HIV + in October 1997. When she first presented, she not only had full-blown AIDS, but also suffered for severe furunculosis and vaginal candidiasis. She took oral MSP for forty-five days before she received her first IV infusion. All of her other conditions were resolved with oral MSP therapy. A herxheimer-like reaction began about 2 � hours after beginning the infusion. The reaction was manifested by headaches, myalgias, and inability to sleep, and lasted for about 8 hours. By 10:00 a.m. The next morning, she felt fine and ate a large breakfast.
GH is a white male (DOB 1948), who has been HIV + SINCE 1985. GH began taking MSP 400 PPM 1 tsp. TID on 4 April 1998. His HIV Ė 1 RNA (viral load) test on 9 June 1998 was 13,752 copies/ml. On 10 June 1998 he was given an infusion of MSP 400 PPM. He continued oral MSP through the end of July 1998. On July 20, a second HIV Ė 1 RNA test was performed, which revealed a dramatic drop of viral load to 2,215 copies/ml (Fig. 3).
Adverse effects noted by all subjects to a greater or lesser degree were (Jarish) Herxheimer-like reactions, lasting from 2-8 hours. These reactions, which usually started from 1-4 hours after the conclusion of the infusion included nausea, vomiting, fever, myalgias, and headache. The reaction appeared to decrease with repeated infusions. Whether this reaction was a true Herxheimer reaction or [not=NOT] an inflammatory effect of the silver has not been conclusively determined. However, any damage [there is NO damage] appears to be self-limiting and rapidly reversible, as demonstrated by APís rapid rebound in hematological status, despite an intervening 400-PPM infusion.
McFarland regrets the admittedly fragmentary data. There are several reasons for this. McFarland, as stated previously, was a businessman. He had no scientific or medical training other than that which he obtained as an avid reader of medical books and what he gleaned from discussions with his physician and scientist friends. He was absolutely convinced of the efficacy of mild silver protein as a broad-spectrum anti-infective agent, based on his personal experience and those of his friends. He was positive it would be efficacious as well on many difficult to treat or even "non-treatable" illnesses. He believed that if he could demonstrate its safety and efficacy on a few severely ill patients, many sick people and their physicians would rapidly avail themselves of this innovative and relatively inexpensive therapy.
A large part of his confidence was based on individuals research after MSPís manufacture by Bayer & Company and Merck and Company had ended. MSP was also dropped from the USP and (34, 35, 36, 37,) NF Formularies shortly before 1970. This later research has shown potentiators and carriers to be paramount in MSPís anti-infective success. Particle size, which is a main determinant of efficacy, is now controlled by these potentiators. To prove his case, he chose among the most difficult conditions there areóAIDS, Lyme Disease, and Hepatitis C. He advertised for experimental subjects who suffered from these conditions. McFarland set up the protocol himself, after consulting with physicians in Mexico, Cuba, and the U.S. However, the physicians only made recommendations to him. McFarland had the final say. No physician was "in-charge," although McFarland hired physicians to perform all medically related procedures. All patient information and laboratory data are derived from patient records and laboratory reports. Unfortunately, once the patientís physicians found out about the "experiments in Mexico" McFarlandís ability to obtain follow-up medical records diminished dramatically. Despite records release forms from each subject, and intervention by attorneys, the local physicians and the state of Louisiana largely refused to cooperate. Also, McFarland learned belatedly that his subjects were less than responsible and were not interested in continuing treatment beyond the point that they felt well enough to return to their former destructive lifestyles. Consequently, they were erratic in following through with their treatments, and did not greatly assist him in obtaining follow-up records. In retrospect, he realizes he should have arranged for the study to be conducted by a physician, under more controlled conditions, so that complete records could have been maintained. McFarland relied on the federally funded "No Aids Project" (in which all of the subjects had been enrolled) for two reasons. First, as economy measure since he had funded the entire trial out of his own pocket. This included round-trip tickets to Mexico, room, board, medical tests and health care for the patients. The other reason was to lend credibility to his study. He believed that the quasi-official and totally non-biased medical records maintained by the "No Aids Project" would lend credibility to his study. However, this plan turned out to be disappointing, as the physicians and administrators of the No Aids Program became a major stumbling block in their repeated refusal to release records of these patients.
All three subjects experienced a dramatic reversal in what had been their rapidly deteriorating clinical condition.
This change was so dramatic, in fact, that all felt well enough to return to their former lifestyles. Unfortunately, they did not maintain the lifestyle changes recommended by their physicians, and two (AP and GH) moved out of town. RC is actively employed, but declines further treatment, as he does not feel ill. The last McFarland heard from AP and GH was that they also did not feel ill and saw no need to continue his treatments. As far as we know, all three are still alive, and two (RC and GH) are actively employed. Nevertheless, as fragmentary and incomplete as these data and records are,
we believe the results are so dramatic that they deserve publication. The dramatic reduction in viral load in these three subjects is certainly no coincidence and cannot be ignored.
We wish to see long-term follow-up, and to see how low and for how long the viral load could be reduced, and to monitor changes in CD4/CD8 ratios. However, such changes take more time than these patients were willing to give in continuing their treatments. As flawed as this study is, we believe McFarland has accomplished several things.
First, he demonstrated the apparent safety of intravenous MSP at a concentration of 400 PPM, confirming many of the studies from the 20ís, 30ís and 40ís.
Second, he also demonstrated that high concentrations are probably toxic, as demonstrated by the dramatic drop in APís hematological status following the 1,500-PPM infusion. [You do NOT NOT NOT use 1,500 PPM for intervenous application]. [You DO use 10,700 sublingually
(in your mouth under the tongue-hold there for 2 minutes-so that it goes into your bloodstream like a nitroglycerine pill) with NO SIDE EFFECTS].
Third, and most important, he demonstrated theÖ
ability of MSP to dramatically reduce the viral load
and cause clinical reversals [back to health] of rapidly deteriorating patients with HIV.
Early indications from McFarlandís work with Lyme Disease, Arthritis, Influenza and Hepatitis C (confirmed by our own preliminary experience) is that MSP appears to be effective in these conditions as well. Results for these conditions will be published separately.
Intravenous Mild Silver Protein 400 ppm appears to be safe, effective virucidal agent in HIV + patients. Although the optimum dosage, frequency and half-life of infusions has not been determined, it appears that one or two infusions weekly appears to be a safe and effective regimen. We believe the frequency should be adjusted downward based on the presence and severity of Herxheimer-like reactions. The use of MSP in other conditions is currently being evaluated.
References and Publications of Interest:
Thompson, N.R. Comprehensive Inorganic Chemistry, Vol. 5 ch. 28, Elmsford, N.Y.: Perganton Press, 1973. Duhamel, B. Electric Metal Colloids and Their Therapeutical Applications Lancet, 1912, Jan. 13 Searle, A. The Use of Colloids in Health and Disease, London: Constable & Co, 1920 pp 67-111. Legge Roe, A. Collosol Argentum and its Optalmic Uses, Br. Med Jan 1916, Jan-June, 136-141. Van Amber Brown, G. Colloidal Silver in Sepsis. Am J. Obstetrics, 1916, Jan-June, 136-141. Hill, W and Pillsbury, D Argyria- The Pharmacology of Silver, Baltimore: Williams & Wilkins, 1939. Romans, I Silver Compounds and Oligodynamic Metals in Antiseptics, Disinfectants. Fungicides and Chemical and Physical Sterilization, 1954, G. Reddish, ed., Philadelphia: Lea & Febiger, 380-428. Committee on National Formulary, The National Formulary, Tenth Edition, American Pharmaceutical Association, Washington, D.C., 1955. Anonymous, Argonin, Protorgol, Merckís Manual, Merck and Company, New York, 1899. pp. 19, 59. Fantus, Dinkelspiel et al, Merck Manual (Materia Medica), Rahway New Jersey, 1940, p. 1387 Taberís Cyclopeidic Medical Dictionary, 1940, p A-91, s-48, s-63, 1940 (title page missing) Ackerman, L., Baron, F et al. Blakistonís New Gould Medical Dictionary, Blackiston Company, Maple Press, York, Pennsylvania, 1949, p. 934 Stecher, Finkel et al, Merck & Company., Rahway N.J. Mild Silver Protein, Merck Index, 1960, p. 686.
An interview with Bill McFarland
With every subscription
renewal form I send a questionnaire asking what folks would like to see in The
Moneychanger. One gentleman wrote, ďWrite something about colloidal silver. It
saved my life!Ē Well, Iíve used it myself, and so has my whole family, with
great results. So I was gunning for a chance to write about it when I found out
about Bill McFarland and mild silver protein.
Bill McFarland grew up in Palestine, Texas. After graduating from high school in 1969, he went to the University of Texas at Austin where he studied petroleum engineering and graduated with a double major in business. Working for Gulf Oilís environmental section he dealt with state and federal governments, and then went to work for independent oil companies. He several businesses in Belize and Central America. In the 1970s he got involved with vitamins and nutritional support. He became acquainted with various forms of silver products in 1994. In 1995 he began to put together groups in the United States and abroad to research Mild Silver Protein (MSP). They began with one form of MSP but have kept on perfecting it and enhancing its ability to kill viruses, bacteria, and funguses. The mild silver protein was made in 1891, as reflected by the Merck manuals of that time. In the early 1960s it fell into disuse thanks to antibiotics and new drugs promoted by the pharmaceutical industry.
You can contact Mr. McFarland at MSP Research, 24619 Potter Road, Opp, Alabama 36467; (334) 493-0420. Just to keep things on the up and up, Bill also kindly sent me samples of his products to try, including some MSP solution to try on our mastitis plagued milch cow. We also used MSP mixed with DMSO and MSM powder to spray on cuts, sores, and blisters on our horses. The result there was very speedy healing with no complications.
Moneychanger: If MSP has been in the Merck manual since 1892 then itís not patentable, is it?
McFarland: That is correct.
Moneychanger: That obviously would effect whether drug companies wanted to manufacture and promote it?
McFarland: Drug companies would not want to make it because the competition would be everywhere so the profit margin would be tiny. Anyone who wanted to manufacture the original MSP could if he had the means.
Moneychanger: Sulfa drugs and penicillin came on a little before World War II, and then really skyrocketed. Until they came along, silver was the most effective antibiotic agent known, wasnít it?
McFarland: In fact it was the drug of choice in hospital settings and doctorís clinics all over the world, but the patient was not given the product to take home with him. He actually had to go to the doctorís office or to the hospital every day for a dose of silver.
Moneychanger: That would be colloidal silver1 or mild silver protein?
McFarland: Mild silver protein.
Moneychanger: Both topically and internally?
McFarland: Yes. It was widely used in Germany in surgery. Surgeons actually sprayed it onto open cuts and wounds during surgery. They used it both to keep infections from intruding into the wound, and to suppress infectious agents that might come out of a cyst or boil. After the turn of the century that use spread to the US and other countries.
Moneychanger: Silver itself has no caustic effect on the body? What about other side effects?
McFarland: Some forms of silver do have side effects, for example, silver nitrate and silver nitrite. However, mild silver protein is not made with the same ingredients nor does it harm the body. The mild silver protein that we manufacture at MSP Research is non-toxic. In our Lyme disease clinical trial some people have consumed over 200 four-ounce bottles of MSP at four hundred parts per million (ppm) in 18 months. After numerous blood tests, urinalysis, and hair analysis, they donít show any accumulation of nitrates or nitrites or other toxic build-up.
Moneychanger: The bloody shirt that some people raise about using silver as an antibiotic agent is argyria, also called silver poisoning. Really ďpoisoningĒ is a misnomer because it doesnít really poison anybody. They donít lie down on the dirt and die; they just turn blue.
McFarland: That is correct, and the bluish tinge is permanent. However, you can remove it with EDTA chelation. No individual who has taken part in any of my studies and trials, or has consumed large quantities of the product has developed argyria. We know of one doctor who has treated one patient with argyria. He got that from consuming his own home made colloidal silver preparations for a couple of years. He had Lyme disease and he was drinking several quarts of home made colloidal silver weekly. Over a two-year period his skin did turn ashen grey. He also had toxins in his system which the doctor believed came from impurities in the silver rods he was using. With just a few chelation sessions the greyish discoloration disappeared. By the way, right after that the patient entered my clinical studies involving Lyme disease. After taking 15 bottles of MSP orally and seven IV infusions, he is now asymptomatic and has returned to running 10K races in Pensacola, Florida.
Moneychanger: What about these little home silver colloid generators? Itís just a pair of alligator clips that you can buy from Radio Shack and three nine-volt batteries. You clip onto two pure silver coins or rods, suspend them in distilled water, and then hook them up to the batteries. That makes colloidal silver solution. Whatís wrong with that?
McFarland: First off, itís mostly an ionic solution with very little colloidal silver. Itís not stable because it wonít stay in suspension. A true colloid will stay in suspension indefinitely.
Moneychanger: And a true colloid contains the elemental form of silver, not some ionic form?
McFarland: Right. The particle size is also very large, microns as itís being made. As soon as you turn the electricity off, (whether you use a 110 volt or 9-volt DC source) your particles start clumping together because they attract each other. The particles then become much larger than micron size. You can actually see the particles accumulating, like grains of sand, in the bottom of the jar as soon as you turn the electricity off. That has to be consumed immediately for any benefit whatsoever. Thereís no way to stabilize the product, and its strength is three to five parts per million. Thatís quite a bit lower than the product I make at 400 parts per million.
Moneychanger: The particle size makes a big difference, too, doesnít it?
McFarland: According to all the biochemists that we have ever worked with, the ideal particle size for absorption into body tissue is between one and 100 nanometers. The micron size created by the colloidal generators is several thousand times larger than that.2
Moneychanger: Then these little generators produce something ionic rather than elemental, i.e., not truly a colloidal suspension.
Second, what colloid there is consists of a very large particle size.
McFarland: Right, and that is very difficult for the body to use, although some people have succeeded in treating sore throats and minor ailments with it. The product that I have developed was not intended necessarily for colds and sore throats, although itís very effective for those. We tried to perfect something that could be used for life threatening situations or very serious illnesses like HIV, AIDS, Lyme disease, Hepatitis A, B, and C.
Moneychanger: In other words, diseases that do not respond to the available antibiotics.
McFarland: Yes. In fact, most of these diseases in advanced stages do not respond at all to any of the known pharmaceuticals available today.
Moneychanger: Iíd like to point out that using silver in medicine is not some goofy alternative that just popped up last week.
McFarland: Actually, it was and is mainstream medicine.
Moneychanger: Today physicians use silver by itself or with mild electric current to heal persistence bone infections, for example, and many other uses in medicine. Itís used also in water purification, where youíre relying on that same anti-biotic effect of silver to purify water. By the way, that silver trick has been used since the most ancient times. On their ships the Greeks used to carry silver vessels for water. Colonial Americans would put a silver coin in a cask of coin to keep it fresh.
McFarland: Or in milk.
Moneychanger: The point here is that the migration of elemental silver off a coin into water would be tiny, an incredibly small amount. Yet from the most ancient times people have noticed this antibiotic effect of silver. Not only that, but also the presence of silver seems to promote healing, not just kill pathogens. And I havenít even mentioned Silvadeneģ (a sulfa drug containing elemental silver), which has a great success story treating burns.
McFarland: We are seeing acceptance of MSP grow among mainstream doctors. We already sell to a lot of naturopaths, chiropractors, dentists, and veterinarians. We have customers with dog kennels and vets whoíve found the product effective in treating parvo and babesia and controlling E. coli. Vets are putting it in water for dogs and cats and goats and horses and cows. Iíve treated goats and cows with mastitis and other infections. But mild silver protein is not a miracle cure all, and with many diseases it also acts slowly. People expect to get immediate results, and they want it cherry flavoured. Well, I canít do that.
Moneychanger: The real attraction of mild silver protein comes from emerging strains of super-bugs resistant to antibiotics. Weíve reached a stage where the use (or rather, overuse) of antibiotics has caused a severe problem: antibiotics have actually helped breed stronger strains of pathogens. One dose of the antibiotic kills off a lot of them, but the ones it doesnít kill may develop a resistance to that antibiotic. When they reproduce youíve created a super bug.
McFarland: Another problem created by antibiotics is systemic candida infections. Thatís an overgrowth of the yeast that normally lives in the small intestine. With the overuse of antibiotics it migrates out into the stomach, goes through the stomach wall, into the bloodstream and out into the entire body. Whenever you feed it sugar, drink cokes, eat Ding-Dongs, bread or any other carbohydrates that converts to sugar in your stomach, youíre feeding the yeast and it grows and grows.
Moneychanger: The candida infection most people know is the vaginal yeast infection.
McFarland: Thatís how it usually appears in females at first, but once it goes systemic they have sore throats, ear infections, thrush on the tongue, low energy levels, and many become unable to work. The end result is that the victim becomes housebound. Then they become susceptible to other diseasesóMS, lupus, Lyme disease, Epstein-Barr, and other infections that basically incapacitate them. Sometimes doctors send them to a psychiatrist because they can find no physical reason for their illness. Thatís when they turn to alternative health practitioners. Mild silver protein may offer those people hope.
Moneychanger: But then again, itís not a magic wand.
McFarland: And it doesnít do it immediately. Often other supplements are necessary.
Moneychanger: Since silver apparently kills mechanically, organisms canít become resistant to it, any more than a fly can build up a resistance to a properly applied fly swatter.
McFarland: In studies conducted by the University of Florida or Vitamin Research Products We have not found any bacteria, virus, or fungus that was resistant to our Silver 400. We also supply MSP under private label to some large supplement companies, and none of them has reported any resistant organism.
Moneychanger: You would use MSP on yourself?
McFarland: I have used this product on myself. I have consumed as much as 8 or 9 ounces at one time with no side effect whatsoever. Iíve taken an IV with 4 ounces of 400 ppm MSP with no side effect except a mild headache for a few minutes.
Moneychanger: How has your MSP worked in clinical trials?
McFarland: We first did clinical trials with HIV. We worked with seven patients in Mexico and the US. Those were pared down to three cases which were reported in the ACAM journal in April 2001. Before that a small article appeared in the January 2001 Townsend Newsletter for Doctors & Patients. About two weeks ago the Florida Chiropractic Associationís feature article focused on our MSP.
Moneychanger: I notice that all the people and places that you mention stand outside the popular medical establishment. ACAM Ė American College for the Advancement of Medicine Ė is largely composed of physicians who do chelation therapy, which most of the profession ignorantly disdains. In Mexico thereís a lot more openness for all kinds of medical practice. And chiropractors arenít exactly welcomed by the medical establishment. How big was the sample size in the clinical trial? Three?
McFarland: The original study was done with seven individuals. The published literature deals with only three individuals.
Moneychanger: What were the results?
McFarland: One individual began confined to bed, unable to walk. Before the treatments his viral load was over 750,000, the detectable limits of all testing in this country. He had full-blown AIDS as well as other viral, bacterial, and fungal infections. After 60 daysí on MSP his viral load dropped to around 400. Thatís at the bottom limit of detectability.
Moneychanger: You administered the MSP intravenously?
McFarland: Yes, but first he took MSP orally for several weeks to help lower the viral load and to kill off candida yeast overgrowth as well as other infections. We did that to minimize the effects of a Herxheimer reaction, a massive die-off of pathogens. [A JarischĖHerxheimer reaction is a reaction to endotoxin-like products released by the death of harmful microorganisms within the body during antibiotic treatment. Efficacious antimicrobial therapy results in lysis (destruction) of bacterial cell membranes, and in the consequent release into the bloodstream of bacterial toxins, resulting in a systemic inflammatory response. JarischĖHerxheimer reactions can be life-threatening as they can cause a significant drop in blood pressure and cause acute end-organ injury, eventually leading to multi-organ failure from the pileup of dead pathogens in the body].
We didnít want to harm these people, and since this was the first time that MSP in its present form had been given intravenously, we wanted to be very cautious. Several doctors are administering MSP intravenously in this country and abroad. They give at least 30 days oral treatment with MSP while trying to boost the immune system, change diet, and reduce the incidence of candida. In all cases, whether HIV, Hepatitis A, B, or C, we are seeing candida yeast overgrowth. Thatís due partly to overuse of antibiotics and partly to poor diet. As the immune system goes downhill then they become susceptible to a long list of other diseases.
Moneychanger: What is it about silver the kills these pathogens?
McFarland: We arenít sure. It appears that no virus or bacterium that weíve come into contact with can resist silver. The silver is bound by a protein molecule and enters the bloodstream throughout the body. Itís absorbed deep into the body. The host or the virus, bacteria, or fungus seem to be attracted by the food-grade protein molecule. We believe the protein molecule is either eaten off and or is attracted to the pathogen, and the silver then either suffocates or shuts down the pathogen. The Herxheimer reaction starts between one and eight hours after an IV infusion. Orally itís the same result. If an individual with a systemic infection takes MSP, sometimes as little as a quarter of a teaspoon, he may get a mild Herxheimer reaction from a very quick die-off of pathogens. We know that it works very quickly and doesnít stay in the body very long. Weíve done extensive hair analysis as well as urinalysis on people whoíve consumed several hundred bottles of MSP and they havenít accumulated any nitrates or nitrites. So we feel the silver dissipates within just a matter of hours or certainly days. Some doctors are giving as many as three IVs a week.
Moneychanger: Itís hard for me to understand that a mixture as weak as 400 parts per million could have much effect. Thatís four ten-thousandths, or .04%. Thatís moving in the direction of homeopathic strength. It doesnít appear to be very strong, yet youíre saying that the clinical results show that even in that strength it massively kills off pathogens.
McFarland: It suffices. We used a 1500 ppm drip on one individual. His vital signs were lowered substantially. We felt like the 400 ppm would work better across the board as a supplement that would not hurt anyone, but would certainly be effective both IV and orally.
Moneychanger: A healthy human being normally has a large population of friendly bacteria in his gut, things like acidophilus. If I swig down MSP wonít it kill off all these normal flora, too?
McFarland: It does not appear to kill all the friendly bacteria, and we donít know why. Over long term use we advise to supplement with some sort of probiotic (acidophilus supplements). However, one man in Oklahoma with Lyme disease in Oklahoma took over 200 bottles accompanied by very little in the way of probiotics. He still didnít have chronic diarrhea, as one would expect if he had killed off all his friendly flora. But by combining MSP with a change of diet, he did get his candida under control.
Moneychanger: So the mild silver protein mightóand I stress the word might because you donít have a whole lot of proof on your side yet, the kind of proof that the so-called scientific community would accept . . .
McFarland: You mean a $20 million double blind study. When I approached MSP in the 1990s I decided that I would be working with people who had life-threatening illnesses but I did not do a double blind study. We took individuals who were truly sick and we worked with them to see if MSP could help. Since then we have enhanced those products and tried to make them more bio-available. We are continuing to do research as money permits, to keep on improving the product.
Moneychanger: But generally that will be people who have given up hope on established medical procedures. People with AIDS, for instance, or Lyme diseaseódiseases that the medical establishment finds very difficult to treat.
McFarland: Correct. We have a small study going on now in Tijuana that involves mycoplasmas. That is also a disease that the traditional medical establishment finds hard to treat successfully. We hope to start a clinical study in Mexico city with Chagas disease, a parasitic disease vectored through mosquitoes. It kills small children. Like Lyme disease or HIV, it weakens the bodyís immune system. The two drugs used on Chagas disease have proven ineffective, and it seems that the pathogen has mutated.
Moneychanger: Where do you plan to take MSP from here? You have another clinical trial scheduled?
McFarland: Vitamin Research Products (VRP) is going to take MSP and use it in South Africa for a 300 person clinical study against HIV. The spin-off of that is that people who are HIV positive or have full-blown AIDS have a multitude of other diseases also, and weíll be able to see how MSP affects those.
Moneychanger: Does VRP sell your products?
McFarland: We sell under our own label and private label for Vitamin Research Products. We manufacture seven silver products: Silver 400, a four ounce bottle of 400 ppm mild silver protein solution; two silver eye-drop solutions; a topical product, effective in gum disease and herpes and fungal skin infections. We also make a nasal spray and a burn mist.
Moneychanger: VRP carries all those?
McFarland: Yes, the 4 ounce bottle of MSP costs between $40 and $50 at retail [ https://invive.com/#allstr ] Ö
Moneychanger: Do you sell the products yourself?
McFarland: I wholesale to over 500 health care professionals in this country, and I sell at retail, too.
Moneychanger: You donít make any claims for the efficacy of mild silver protein?
McFarland: We cannot make any claims. We do have a silver manual to explain how to use the products and we do have extensive anecdotal reports from doctors that we provide to the medical community. And I do seminars.
Moneychanger: Bill, thanks very much for your time and courtesy.
1 To greatly
oversimplify, a colloid is a is Ďa substance in a particularly fine state of
subdivision, much larger than atomic or simple molecular dimensions, but much
smaller than particles visible to the unaided eye.Ē (Encyclopedia Britannica) A
colloidal suspension contains a colloid in some medium, and can be a gas,
liquid, or solid. Examples include smoke, mist, milk, butter, mayonnaise,
cheese, dough, paint, and concrete. A colloid usually does not easily settle
out of the suspension, i.e., unspoiled milk usually doesnít separate into water
and butterfat. A colloidal suspension is not a solution, because it contains
substances which are not broken down into their atomic or molecular parts. A
colloid of silver, for example, contains elemental silver particles in some
medium. A solution, on the other hand, contains the dissociated atomic or
molecular parts. For instance, a solution of silver chloride contains molecules
of the salt, silver chloride, dissociated into its component ions, cations
(positively charged ions) of silver and anions (negatively charged ions) of
chlorine. For a very rough idea of the difference between a colloidal suspension
and a chemical solution, think of throwing sand into unset jello versus
throwing salt into water.
2 One micron is one-millionth of a meter. One nanometer is one-billionth of a meter. One angstrom is one-ten billionth of a meter. The word ďmicronĒ in physical chemistry also refers to any particle with a diameter between .01 and .0001 millimeter.
WARNING & DISCLAIMER: By publishing this material, neither The Moneychanger nor the author/interviewee recommends or endorses any specific treatment or therapy for any physical condition or disease. Neither The Moneychanger nor the author/interviewee guarantees or warrants any results from any treatment discussed, nor assumes any express or implied liability for any use to which the reader puts this information. By this interview, the interviewee does not prescribe any treatment whatsoever for anyone who is not his patient. All the information here is offered for information purposes only, subject to the readerís own research, prudence, and judgment.